doc. MUDr. Daniela Žáčková, Ph.D.
Associate professor, Department of Internal Medicine, Hematology and Oncology
correspondence Address:
Jihlavská 340/20, 625 00 Brno
phone: | +420 532 23 2838, 3603 |
---|---|
e‑mail: |
social and academic networks: |
---|
Total number of publications: 222
2010
-
Imatinib (IMA) plasma concentration (PC) monitoring and its correlation with treatment response in chronic myelogenous leukemia (CML): a single centre experience
Year: 2010, type: Conference abstract
-
Imatinib in the first line chronic myeloid leukemia (CML) treatment. Can we compare the real-life data to clinical trial results?
Year: 2010, type: Conference abstract
-
Imatinib v první linii léčby pacientů s chronickou myeloidní leukemií (CML) v chronické fázi (CP). Můžeme srovnat výsledky z reálné klinikcé praxe s výsledky dosaženými v klinických studiích?
Year: 2010, type: Conference abstract
-
Mechanismy rezistence k imatinibu: laboratorní a klinická rezistence
Year: 2010, type: Appeared in Conference without Proceedings
-
Minimal residual resistance in CML: Stable BCR-ABL gene expression at levels 0.01-0.1% (IS) in the consecutive samples may be associated with BCR-ABL mutation development and MMoR lost in a small number of tyrosine kinase inhibitor responders.
Year: 2010, type: Conference abstract
-
Nová doporučení ELN pro léčbu a monitorování CML
Year: 2010, type: Appeared in Conference without Proceedings
-
Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia.
American Journal of Hematology, year: 2010, volume: 85, edition: 5
-
Sexualita u pacientů s chronickou myeloidní leukémií léčených imatinibem
Česká a slovenská psychiatrie, year: 2010, volume: 106, edition: 5
-
The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population
Year: 2010, type: Conference abstract
-
The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population
American Journal of Hematology, year: 2010, volume: 85, edition: 7, DOI